A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Inclusion Criteria: * Subject has a body mass index (BMI) range of 18.5 to 32.0 kg/m\^2, inclusive and weighs at least 50 kg at screening. * Female subject is not pregnant and at least 1 of the following conditions apply: * Not a woman of childbearing potential (WOCBP) * WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 30 days after final investigational product (IP) administration. * Female subject must agree not to breastfeed starting at screening, throughout the study period and for 30 days after final IP administration. * Female subject must not donate ova starting at first administration of IP, throughout the study period and for 30 days after final IP administration. * Male subject with female partner(s) of childbearing potential (including breastfeeding partner\[s\]) must agree to use contraception throughout the treatment period and for 30 days after final IP administration. * Male subject must not donate sperm during the treatment period and for 30 days after final IP administration. * Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy, throughout the study period and for 30 days after final IP administration. * Subject agrees not to participate in another interventional study while participating in the present study. Exclusion Criteria: * Subject has received any investigational therapy within 28 days or 5 half-lives, whichever is longe…